TAK-906

DRUG4 trials

Sponsors

Takeda, Millennium Pharmaceuticals, Inc.

Conditions

Healthy VolunteersJapanese Healthy Adult Male Participants

Phase 1

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

CompletedNCT03237156

TakedaJapanese Healthy Adult Male Participants

Start: 2017-08-07End: 2017-10-07Updated: 2021-01-12

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

CompletedNCT03849690

Millennium Pharmaceuticals, Inc.Healthy Volunteers

Start: 2019-02-27End: 2019-04-15Updated: 2021-06-15

A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

CompletedNCT04121078

Millennium Pharmaceuticals, Inc.Healthy Volunteers

Start: 2019-10-15End: 2019-11-16Updated: 2020-12-09

Bioavailability and Food Effect Study of Two Formulations of TAK-906

WithdrawnNCT04831502

TakedaHealthy Volunteers

Start: 2021-04-02End: 2022-02-02Updated: 2022-03-24

Related Papers

The pharmacokinetics of oral trazpiroben (<scp>TAK</scp>‐906) after organic anion transporting polypeptide <scp>1B1</scp>/<scp>1B3</scp> inhibition: A phase I, randomized study

Clinical and Translational Science2022-04-236 citations

Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole

Clinical and Translational Science2022-02-262 citations